Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002028
Status:
COMPLETED
Last Update Posted:
2007-08-16
First Post:
1999-11-02
Brief Title:
A Treatment IND Investigational New Drug Protocol for the Use of Videx 23-Dideoxyinosine ddI in Patients With Acquired Immunodeficiency Syndrome AIDS or AIDS- Related Complex ARC Who Are Intolerant to Zidovudine Retrovir
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Treatment IND Investigational New Drug Protocol for the Use of Videx 23-Dideoxyinosine ddI in Patients With Acquired Immunodeficiency Syndrome AIDS or AIDS- Related Complex ARC Who Are Intolerant to Zidovudine Retrovir
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this treatment IND protocol is to make didanosine ddI available to patients with HIV infection suffering from AIDS related complex ARC or AIDS who have developed documented intolerance to zidovudine AZT and cannot enter a Phase II ddI program due to protocol exclusion or geographic location
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 454-999-001 | None | None | None |